Prosecution Insights
Last updated: October 21, 2026
Application No. 18/839,110

SUBSTITUTED FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USES THEREOF

Non-Final OA §112
Filed
Aug 16, 2024
Priority
Feb 25, 2022 — CN 202210178818.7 +2 more
Examiner
HABTE, KAHSAY
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Suzhou Yabao Pharmaceutical R&D Co., Ltd.
OA Round
1 (Non-Final)
85%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allowance Rate
1394 granted / 1642 resolved
+24.9% vs TC avg
Moderate +8% lift
Without
With
+7.5%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 8m
Avg Prosecution
54 currently pending
Career history
1675
Total Applications
across all art units

Statute-Specific Performance

§101
3.3%
-36.7% vs TC avg
§103
6.3%
-33.7% vs TC avg
§102
17.0%
-23.0% vs TC avg
§112
50.5%
+10.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1642 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-18 are pending in this application. Election/Restrictions Applicant’s election without traverse of Group I and a species W = N in the reply filed on 09/29/2026 is acknowledged. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-5, 7 and 15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention: a. Claim 1 and claims dependent thereon are rejected because the phrase “an isotopically labeled compound” is indefinite. What is covered by “an isotopically labelled compound” and what is not? What does an isotopically labeled compound look like? Where are the examples? The examine recommends that applicants delete said phrase. b. Claim 1 and claims dependent thereon are rejected because the term “polymorph” is indefinite and unclear. What is covered and what is not? What are the different crystalline forms? Where is the x-ray diffraction data for the polymorph? It is recommended that applicants recite x-ray diffraction data or delete said term from the claims. c. In claim 3, there is no definition for the variables R11 and R12. The phrase “R11 and R12 are.” appears to be incomplete. The claim ends with the word “are”. Information Disclosure Statement 5. Applicant’s Information Disclosure Statement, filed on 06/05/2026 and 08/16/2024, has been acknowledged. Please refer to Applicant’s copies of the 1449 submitted herewith. Claim Objections 6. Claim 5 is objected to because of the following informalities: The chemical structures in claim 5 have faded bonds. Note that the previously deleted compounds 561 and 562 were drawn properly compared to compounds 561 and 562 that are added later (see below). PNG media_image1.png 178 508 media_image1.png Greyscale PNG media_image2.png 159 467 media_image2.png Greyscale Appropriate correction is required. Conclusion 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte Ph.D. whose telephone number is (571)272-0667. The examiner can normally be reached on 8:30 - 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JEFFREY MURRAY can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Kahsay Habte/ Primary Examiner, Art Unit 1624 October 12, 2026
Read full office action

Prosecution Timeline

Aug 16, 2024
Application Filed
Oct 14, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12765554
SOLID PESTICIDAL FORMULATION
3y 5m to grant Granted Oct 20, 2026
Patent 12759968
(S)-3-AMINO-4-(DIFLUOROMETHYLENE)CYCLOHEXENE AND CYCLOHEXANE CARBOXYLIC ACID AND USES THEREOF AS SELECTIVE INACTIVATORS OF HUMAN ORNITHINE AMINOTRANSFERASE (hOAT)
3y 0m to grant Granted Oct 13, 2026
Patent 12760031
PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS
2y 4m to grant Granted Oct 13, 2026
Patent 12753159
3-HYDROXYADIPIC ACID 3,6-LACTONE COMPOSITION
3y 1m to grant Granted Oct 06, 2026
Patent 12753170
OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF
2y 1m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
85%
Grant Probability
92%
With Interview (+7.5%)
1y 8m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1642 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month